Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)

1. Age :18-80 years old , male or female;

2. one of the following situations: A.recent ischemic stroke or TIA (within 3 months) B. One or more vascular risk factors including hypertension, diabetes mellitus, or dyslipidemia, with multiply lacunar infarctions(≥2) or extensive white matter lesions（Fazekas ≥2） or multiply microhaemorrhage(≥2) showed on CT/MR.

3. Fe deficiency （serum ferritin<20µg/L）or Hemoglobin deficiency(≥60 g/L and <120g/L for female,or ≥60 g/L and <130g/L for male)

4. Signed informed consent

1. CT/MR showed Intracranial haemorrhage or non-cerebral vascular disease (eg. intracranial tumors, multiple sclerosis);

2. Patients who Can not cooperate with the completion of neuropsychological evaluation for Severe hearing impairment, visual impairment, unilateral neglect, or dyskinesia;

3. Patients with Severe anemia with Hemoglobin<60 g/L;

4. Patients with thalassemia, megaloblastic anemia or erythronoclastic anemia.

5. Patients with Mental illness or schizophrenia;

6. Patients who were diagnosed definitely as Alzheimer's disease;

7. Patients having history of taking drugs including Cholinesterase inhibitors、NMDA antagonists、5-hydroxytryptophan receptor antagonists、pyrrolidone and other definite drugs for improving cognition(e.g. donepezil、Galanthamine、Memantine、huperzine A、oxiracetam、aniracetam、piracetam、butyphthalide) within 3 months before randomization；

8. Patients with severe liver or kidney insufficiency(ALT>twofold upper normal limit or Aspartate Aminotransferase>twofold upper normal limit; Cr>1.5 times upper normal limit or Glomerular Filtration Rate<40 ml/min/1.73m2）;

9. Patients with Severe untreated urinary tract infection;

10. Patients with hemochromatosis or hemosiderosis(e.g. Iron lung deposition);

11. Patients with Iron allergy or other contraindications of using Iron；

12. Pregnant or childbearing-age women；

13. Patients who are undergoing experimental drugs or device tests;

14. Patients Unable to finish the follow-up of 3 months or 1 year due to geographical factor or other reasons;

15. Patients or legal representatives refuse to participate.